Jazz Pharmaceuticals (NASDAQ:JAZZ) Earns Overweight Rating from Piper Sandler

Piper Sandler reaffirmed their overweight rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report released on Thursday morning,Benzinga reports. The brokerage currently has a $163.00 price target on the specialty pharmaceutical company’s stock, down from their previous price target of $166.00.

A number of other brokerages have also weighed in on JAZZ. TD Cowen lowered their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, November 7th. Cantor Fitzgerald reiterated an “overweight” rating and set a $140.00 price objective on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. JPMorgan Chase & Co. upped their target price on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. Finally, Wells Fargo & Company cut their price target on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a research note on Thursday, August 1st. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $175.33.

Jazz Pharmaceuticals Stock Up 1.3 %

JAZZ stock opened at $126.67 on Thursday. The stock’s 50 day simple moving average is $113.65 and its 200 day simple moving average is $110.73. The company has a market cap of $7.66 billion, a P/E ratio of 17.84, a price-to-earnings-growth ratio of 1.05 and a beta of 0.57. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals has a fifty-two week low of $99.06 and a fifty-two week high of $134.17.

Insider Buying and Selling

In other news, EVP Neena M. Patil sold 3,700 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares in the company, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the sale, the chief executive officer now directly owns 428,976 shares in the company, valued at $47,547,699.84. This trade represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,110 shares of company stock worth $720,160. 4.20% of the stock is owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

A number of large investors have recently bought and sold shares of JAZZ. Versant Capital Management Inc lifted its position in shares of Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 269 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in Jazz Pharmaceuticals in the 2nd quarter valued at about $29,000. EverSource Wealth Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 97 shares during the last quarter. GAMMA Investing LLC boosted its position in Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after purchasing an additional 116 shares during the period. Finally, Gladius Capital Management LP purchased a new position in shares of Jazz Pharmaceuticals in the second quarter worth about $33,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.